Aussie firm Proteomics International said this week it has developed a new peptide drug-discovery process based on venom from scorpions, spiders, and centipedes.
Called Bioven, the process is a new way to validate potential peptide drug candidates. It combines mass spectrometry with proprietary algorithms "to determine peptide identity and to predict, by homology matching, the function of the peptides," the company said in a statement.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
